Biostem Technologies Valuation
| BSEM Stock | USD 15.49 0.49 3.27% |
At this time, the firm appears to be overvalued. Biostem Technologies shows a prevailing Real Value of $14.04 per share. The current price of the firm is $15.49. Our model approximates the value of Biostem Technologies from analyzing the firm fundamentals such as Shares Outstanding of 9.24 M, return on equity of -2.21, and Operating Margin of (18.22) % as well as examining its technical indicators and probability of bankruptcy. . In general, most investors favor obtaining undervalued instruments and abandoning overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
Please note that Biostem Technologies' price fluctuation is slightly risky at this time. Calculation of the real value of Biostem Technologies is based on 3 months time horizon. Increasing Biostem Technologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Biostem otc stock is determined by what a typical buyer is willing to pay for full or partial control of Biostem Technologies. Since Biostem Technologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biostem OTC Stock. However, Biostem Technologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.49 | Real 14.04 | Hype 15.49 |
The intrinsic value of Biostem Technologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biostem Technologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biostem Technologies helps investors to forecast how Biostem otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biostem Technologies more accurately as focusing exclusively on Biostem Technologies' fundamentals will not take into account other important factors: Biostem Technologies Total Value Analysis
Biostem Technologies is currently forecasted to have valuation of 37.89 M with market capitalization of 34.19 M, debt of 1.32 M, and cash on hands of 1.37 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biostem Technologies fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
37.89 M | 34.19 M | 1.32 M | 1.37 M |
Biostem Technologies Investor Information
The company recorded a loss per share of 0.58. Biostem Technologies had not issued any dividends in recent years. The entity had 1:400 split on the 27th of January 2015. Based on the key indicators related to Biostem Technologies' liquidity, profitability, solvency, and operating efficiency, Biostem Technologies is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Biostem Technologies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biostem Technologies has an asset utilization ratio of 94.51 percent. This suggests that the OTC Stock is making $0.95 for each dollar of assets. An increasing asset utilization means that Biostem Technologies is more efficient with each dollar of assets it utilizes for everyday operations.Biostem Technologies Profitability Analysis
The company reported the previous year's revenue of 2.52 M. Net Loss for the year was (2.39 M) with profit before overhead, payroll, taxes, and interest of 163.78 K.About Biostem Technologies Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Biostem Technologies. In general, an absolute valuation paradigm, as applied to this otc stock, attempts to find the value of Biostem Technologies based exclusively on its fundamental and basic technical indicators. By analyzing Biostem Technologies's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Biostem Technologies's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biostem Technologies. We calculate exposure to Biostem Technologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biostem Technologies's related companies.BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida. Biostem Technologies is traded on OTC Exchange in the United States.
8 Steps to conduct Biostem Technologies' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Biostem Technologies' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Biostem Technologies' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Biostem Technologies' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Biostem Technologies' revenue streams: Identify Biostem Technologies' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Biostem Technologies' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Biostem Technologies' growth potential: Evaluate Biostem Technologies' management, business model, and growth potential.
- Determine Biostem Technologies' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Biostem Technologies' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Biostem Technologies Growth Indicators
Investing in growth stocks can be very risky. If the company such as Biostem Technologies does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 9.2 M | |
| Retained Earnings | -28.2 M |
Other Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.